Conference Coverage
Conference Coverage
New tool predicts late recurrence in breast cancer
Major Finding: Among patients who remained disease free at 5 years, the 61% with a low baseline BCI score had a 3.5% rate of distant recurrence...
Conference Coverage
Lenalidomide branches out to lymphoma therapy
Major Finding: In a phase II study, lenalidomide added to CHOP chemotherapy and rituximab produced a 92% overall response rate in elderly patients...
Conference Coverage
Risk of anal cancer is high in HIV-infected people
Conference Coverage
New geriatric assessments aid cancer treatment decisions
Conference Coverage
SLN surgery may suffice for node-positive breast cancer
Major Finding: SLN surgery correctly identified axillary nodal status in 91.2% of patients.
Conference Coverage
Diabetes confers 27% increase in breast cancer risk
Major Finding: Diabetes is associated with a 27% increased risk of breast cancer, with the elevated risk restricted to postmenopausal women with...
Conference Coverage
'Highest response rate ever reported' in relapsed mantle cell lymphoma
Major Finding: In an efficacy cohort of 110 patients with relapsed or refractory mantle cell lymphoma, 22% had a complete response and 46% a...
Conference Coverage
HERA: Trastuzumab survival benefit strong at 8 years
Major Finding: At 8 years of follow-up, women who received 1 year of adjuvant trastuzumab had a 24% reduction in risk of all-cause mortality...
Conference Coverage
Bevacizumab misses - again - for breast cancer
Major Finding: Median 32-month rate of invasive disease-free survival was 85.5% with adjuvant chemotherapy plus a year of bevacizumab and 84.1%...
Conference Coverage
Trastuzumab survival benefit still significant 10 years later
Major Finding: By year 10, 84% of those in treated with trastuzumab and paclitaxel were still alive vs. 75% of those given paclitaxel alone.Data...
Conference Coverage
Eribulin fails to best capecitabine in advanced breast cancer
Major Finding: Eribulin was not significantly better than capecitabine in median overall survival (15.9 vs. 14.5 months, P = .056) or progression-...